Strong progress has already been seen on UK uptake of rituximab (MabThera), infliximab (Remicade) and etanercept (Enbrel) biosimilars, with the latter two rivalling Humira in indications such as ...

2010;10(2):163-175. We searched for clinical trials, cohort studies and registries assessing infliximab or Remicade®, adalimumab or Humira®, or etanercept or Enbrel® for CD. Medline (1950 ...